加载中
Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company focused on developing innovative treatments for individuals battling cancer. Its therapeutic portfolio includes a range of antibodies and small molecules engineered to combat various malignancies, such as prostate, lung, and breast cancer, as well as glioblastoma. Initially incorporated in 2013 under the name NanoGB13, Inc., the enterprise officially adopted its current identity as Kairos Pharma, Ltd. in July 2016. The company's operations are headquartered in Los Angeles, California.
收盘时
US$0.832
+US$0.0217 · +2.68%
盘后
US$0.839
+US$0.007 · +0.84%
10月12日 16:41 ET
盘中时间采用ET。市场数据可能有所延迟。
Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company focused on developing innovative treatments for individuals battling cancer. Its therapeutic portfolio includes a range of antibodies and small molecules engineered to combat various malignancies, such as prostate, lung, and breast cancer, as well as glioblastoma. Initially incorporated in 2013 under the name NanoGB13, Inc., the enterprise officially adopted its current identity as Kairos Pharma, Ltd. in July 2016. The company's operations are headquartered in Los Angeles, California.
日内区间
当前US$0.832
52周区间
当前US$0.832
盘中时间采用ET。市场数据可能有所延迟。
Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company focused on developing innovative treatments for individuals battling cancer. Its therapeutic portfolio includes a range of antibodies and small molecules engineered to combat various malignancies, such as prostate, lung, and breast cancer, as well as glioblastoma. Initially incorporated in 2013 under the name NanoGB13, Inc., the enterprise officially adopted its current identity as Kairos Pharma, Ltd. in July 2016. The company's operations are headquartered in Los Angeles, California.
日内区间
当前US$0.832
52周区间
当前US$0.832
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | — | 16万 USD | 16万 USD | 16万 USD | 9.8万 USD |
| 毛利 | — | −16万 USD | −16万 USD | −16万 USD | −9.8万 USD |
| 研究与开发 | 213.5万 USD | 41.4万 USD | 8.2万 USD | 8.7万 USD | 18.3万 USD |
| 销售、一般及管理费用 | 343.7万 USD | 176.9万 USD | 147.2万 USD | 32.4万 USD | 166.2万 USD |
| 营业费用 | 557.2万 USD | 218.3万 USD | 155.4万 USD | 41.1万 USD | 184.5万 USD |
| 利息收入 | 12.5万 USD | — | — | — | — |
| 利息支出 | — | 85.9万 USD | 9.8万 USD | 47.9万 USD | 20.2万 USD |
| 折旧和摊销 | 16万 USD | 16万 USD | 16万 USD | 16万 USD | 9.8万 USD |
| 营业利润 | −557.2万 USD | −234.3万 USD | −171.4万 USD | −57.1万 USD | −194.3万 USD |
| 净利润 | −544.7万 USD | −260.3万 USD | −181.2万 USD | −105万 USD | −214.5万 USD |
公司数据更新于 2026年10月12日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
